DSIP FAQ: original peptide, testing and safety
A place to resolve the specific terms that turn up in searches, especially when several different questions have been compressed into one phrase.
What does original DSIP mean?
Original DSIP is the nine-amino-acid chain Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, established in the 1977 rabbit characterization. Phospho DSIP and engineered fusion peptides require separate identification. The identity page follows those names back to the substance each describes.
DSIP lab testing
The phrase needs the actual test result behind it. A result about identity or purity answers only the question measured; it cannot establish clinical benefit, human safety or the sterility of material unless that was assessed. There is no approved pharmaceutical DSIP product. “Lab tested” leaves the property being tested unspecified. A useful claim would name it.
DSIP safety data: which human studies exist?
The available human record includes small sleep, pain and withdrawal studies. The withdrawal report named headache as its main side effect. Long-term controlled human safety data, reliable interaction studies and a validated human pharmacokinetic profile remain missing. The safety page covers those gaps alongside the brief reports.
What is the DSIP half life?
Animal experiments in dogs, monkeys and rats put plasma half-life at a few minutes. Human pharmacokinetics remain unvalidated in the research record reviewed for DSIP. That animal clearance finding cannot give a dependable human duration of action or a timing rule.
What are delta sleep inducing peptide side effects?
Headache is the main side effect named in the old withdrawal report. Personal accounts also describe grogginess, delayed sleepiness, nausea and dizziness. Those accounts are anecdotal, not clinical evidence, and provide no measured frequency. The small studies also leave rare and long-term harms unresolved.
Did DSIP work immediately in the sleep study?
The 1981 study found the sleep-promoting effect in the second hour after intravenous administration, with slight arousal in the first. Six middle-aged adults with chronic insomnia took part. That is the timing of an observation in one experiment; no dependable bedtime schedule for human use has been established.
How strong is the sleep evidence?
The small human study reported longer, less interrupted sleep. The 2006 review judged the wider evidence weak and uneven and pointed to clearer effects from structural analogues. I regard the lack of a consistent account across the literature as the central practical problem with the sleep claim.
Which hormones changed after DSIP?
Rats showed growth-hormone responses that studies in women did not reproduce, according to the review of DSIP biology. A human experiment lowered ACTH-like immunoreactivity while leaving cortisol unaffected. Later hormone findings also failed to reproduce earlier effects. Each hormone and study population needs to stay attached to its result.
Is dependence or long-term use understood?
The old human studies were too small and short to establish dependence risk or the consequences of prolonged exposure. Reports that effects fade are anecdotal accounts. The open withdrawal pilot investigated withdrawal from other substances; it was not a test of dependence on DSIP.
Did newer research establish a human treatment?
The 2024 experiment tested a DSIP fusion peptide in mice with experimentally induced insomnia. The 2026 orthopaedics review mentions DSIP without adding a DSIP clinical trial. Neither supplies a modern controlled human treatment result for original DSIP.